RE:RE:RE:RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now October 07, 2022 - Merck KGaA has been investing heavily in its biopharma business as part of an effort to grow to 25 billion euros in global revenues by 2025. Starting next year, its expansion campaign could include M&A.
In a statement ahead of its capital markets day, the global conglomerate said it will consider "larger-scale" acquisitions beginning in 2023.
https://www.fiercepharma.com/pharma/merck-kgaa-will-focus-big-3-business-sectors-consider-large-scale-acquisitions-2023-onwards